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Abstract: Background: The prognostic value of quick sepsis-related organ failure assessment (qSOFA)
outside intensive care units has been criticized. Therefore, we aimed to improve its ability in predicting
30-day all-cause mortality, and in ruling out the cases at high risk of death among patients with
suspected or confirmed sepsis at emergency department (ED) admission. Methods: This study is a
secondary analysis of a prospective multicenter study. We built three predictive models combining
qSOFA with the clinical variables and serum biomarkers that resulted in an independent association
with 30-day mortality, in both 848 undifferentiated patients (Group 1) and in 545 patients definitively
diagnosed with sepsis (Group 2). The models reaching the highest negative predictive value (NPV)
with the minimum expenditure of biomarkers in Group 1 and in Group 2 were validated in two
cohorts of patients initially held out due to missing data. Results: In terms of the area under the
receiver-operating characteristic curve, all six models significantly exceeded qSOFA in predicting
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prognosis. An “extended” qSOFA (eqSOFA1) in Group 1 and an eqSOFA2 integrated with C-reactive
protein and mid-regional proadrenomedullin (eqSOFA2+CRP+MR-proADM) in Group 2 reached the
best NPV (0.94 and 0.93, respectively) and ease of use. eqSOFA1 and eqSOFA2+CRP+MR-proADM
performed equally well in both the inception and validation cohorts. Conclusions: We have derived
and validated two prognostic models that outweigh qSOFA in predicting mortality and in identifying
the low risk of death among patients with suspected or confirmed sepsis at ED admission.
Keywords: sepsis; biomarkers; C-reactive protein; lactate; procalcitonin; mid-regional
proadrenomedullin; soluble tumor necrosis factor receptor-1; soluble triggering receptor expressed
on myeloid cell-1; presepsin; and soluble IL-2 receptor α
1. Introduction
Sepsis is a major cause of mortality worldwide. At emergency department (ED) admission,
the proper assessment of sepsis outcome is vitally important to aid clinical decision making and to
optimize the allocation of critical care resources. In 2016, the SEPSIS-3 Task Force proposed quick
sepsis-related organ failure assessment (qSOFA), a simple and rapid score, to help discriminate sepsis
survivors from non-survivors with a performance at least comparable with that of a sequential organ
failure assessment (SOFA) score [1]. Several studies have demonstrated the usefulness of qSOFA-based
prognostication in patients with suspected sepsis, especially when compared with that of the systemic
inflammatory response syndrome (SIRS) criteria [2]. However, it was not always clearly stated in those
works if patients were included who were initially suspected to have infection, but were adjudicated
not to have infection on expert review. This finding, on one hand, makes those studies’ interpretation
tricky, and on the other hand, it may raise concerns about their generalizability. Given the above
premises, the prognostic value of qSOFA at ED admission has been questioned, especially when
compared with more complex warning systems [2–4].
Six studies [5–10] sought to assess whether the integration of qSOFA with plasma concentrations of
conventional biomarkers of prognosis (C-reactive protein [CRP] [5,6], lactate [7–10], and procalcitonin [5,6])
could improve the performance of qSOFA alone in predicting sepsis outcome: however, the
results were conflicting. In the last 10 years, numerous circulating mediators of host response,
such as mid-regional proadrenomedullin (MR-proADM ) [11], soluble tumor necrosis factor
receptor-1 (sTNFR-1) [12–17], soluble triggering receptor expressed on myeloid cell-1 [18] (sTREM-1),
presepsin [19], soluble phospholipase A2 group IIA (sPLA2GIIA) [20], and soluble IL-2 receptor
α [21] (sIL2Rα) have been associated with poor prognosis in sepsis. Whether contemporary use of
all of these experimental biomarkers could act synergistically with qSOFA in predicting outcome is
unknown. Therefore, in this study, we tested the hypothesis that measuring concentrations of the
aforementioned conventional and experimental biomarkers would enhance the prognostic value of
qSOFA in undifferentiated patients with suspected sepsis at ED admission and in those, among them,
definitively diagnosed with sepsis at the end of clinical work-up.
2. Methods
This study is a secondary analysis of a prospective multicenter study conducted in 5 Italian EDs
during a 2-year period [22]. Its original purpose was to derive and validate a predictive algorithm to
rule out infection in 1132 undifferentiated patients with suspected sepsis who fulfilled at least 2 SIRS
criteria at ED admission. The latter cohort included both patients who received a definitive diagnosis of
infection and those who were deemed not infected (ni-SIRS) at the end of clinical work-up. Exclusion
criteria were age less than 18 years, absence of informed consent, and pregnancy. Etiology, severity,
and source of infection were adjudicated according to a predefined classification system (available
in the Supplement). For this secondary analysis, we reviewed the three clinical variables required to
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calculate the qSOFA score, and the first venous lactate concentration measured at each respective site
in all undifferentiated patients with suspected sepsis. The primary outcome of the present study was
30-day all-cause mortality. The secondary outcome was ruling out the high risk of death.
2.1. Biomarker Measurements
Blood samples for CRP, procalcitonin, sPLA2GIIA, presepsin, sIL2Rα, and sTREM-1 measurements
were collected at ED admission in the entire cohort of undifferentiated patients with suspected sepsis,
as previously reported [22]. MR-proADM and sTNFR-1 were measured specifically for this secondary
analysis in the remaining frozen aliquots of serum. In detail, MR-proADM was assayed by an
automated Kryptor analyzer (Kriptor Brahms AG, Hennigsdorg Germany) in the 1132 undifferentiated
patients with suspected sepsis. Among these patients, in those who were definitively diagnosed with
sepsis (729), sTNFR-1 determinations were carried out by commercial enzyme-linked immunosorbent
assay kits following the manufacturer’s instructions (R&D).
2.2. Statistical Analysis
Categorical data are summarized as percentages and numbers, normally distributed continuous
data as mean ± standard deviation, and non-normally distributed variables as median and
interquartile range. The unpaired Student t test was used, when appropriate, for the comparison of
normally distributed data, while the Mann-Whitney test was used for non-normal continuous data.
The χ2 test or the Fisher test was used, when appropriate, to compare categorical variables expressed
as proportions. Unadjusted odds ratios (ORs) were calculated to assess the independent effect of
qSOFA score, clinical variables, and serum biomarkers on 30-day mortality.
To estimate a multivariable model, two strategies were implemented and compared: one based on
a least absolute shrinkage and selection operator (LASSO) [23], i.e., a penalized logistic regression, and
the other on a standard logistic full-model approach, in both cases starting from all variables significant
at univariable analysis. For the lasso-based procedure, hyperparameter λ (penalty weight) were tuned
with a default grid search implemented in the R “glmnet” library, in a 10-fold cross-validation. The same
conclusions (in terms of the selected variables) were obtained with the two strategies. We therefore
reported as results the odds ratios and corresponding 95% CI, estimated by the standard logistic
regression model. We built three nested-predictive models, including the qSOFA score, the most
significant clinical variables, and the biomarkers selected by the LASSO method. This was done both in
undifferentiated patients with suspected sepsis at ED admission and in those, among them, definitively
diagnosed with sepsis.
Independent predictors were incrementally added to the qSOFA score starting from the easiest
and cheapest to collect in clinical practice (i.e., from the clinical variables), through the conventional
biomarkers and ending with the experimental biomarkers (unavailable for prime time). For the
undifferentiated patients with suspected sepsis, the three predictive models were built as follows:
Model 1 included the qSOFA score and clinical variables; Model 2 encompassed the qSOFA score,
clinical variables, and conventional biomarkers; and Model 3 incorporated all of the above items and the
experimental biomarkers. The same procedure was applied for the patients definitively diagnosed with
sepsis (the models were termed Model 4, Model 5, and Model 6, respectively). Discrimination power
was quantified using C statistics (area under the receiver-operating characteristic curve [AUROC]),
and the De Long test was calculated to compare model AUROCs. According to the Youden Index
method, different cut-offs were estimated between models on the estimated predicted probabilities of
event, and compared in terms of sensitivity, specificity, positive predictive values (PPVs), negative
predictive values (NPVs), and positive/negative likelihood ratios (LRs). The tests between NPVs were
performed using the generalized score statistics [24]. All p values were two sided and considered
significant when <0.05. All analyses were performed using the IBM SPSS statistic 24 software and the
R software, R Core Team (2019), using the libraries “rms,” “Hmisc,”, “glmnet”, “OptimalCutPoints,”
and “DTComPair”.
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3. Results
3.1. Group 1: Undifferentiated Patients with Suspected Sepsis at ED Admission.
Of the 1132 undifferentiated patients with suspected sepsis, 304 were excluded because of missing
data (Figure S1 available in the Supplement). We did not find a statistically significant difference
between complete and incomplete cases except for median Charlson Index, sTREM-1, and presepsin
concentrations (higher in complete than in noncomplete data, p = 0.01). Baseline characteristics of the
828 patients in Group 1 and their etiology of SIRS at the end of clinical work up are summarized in
Table 1.
Table 1. Group 1: baseline patient characteristics and etiology of systemic inflammatory response
syndrome (SIRS) at the end of the clinical work-up.
Survivor n = 680 Non Survivor n = 148 p OR
Male 368 67 0.051 1.426 (0.998–2.038)
Median age (IQR) 78 (69–86) 85 (79–90) <0.001 1.051 (1.032–1.070)
Median Charlson Index (IQR) 2 (1–4) 3 (2–5) <0.001 1.164 (1.085–1.250)
Medain SOFA (IQR) 2 (1–4) 4 (2–6) <0.001 1.337 (1.238–1.444)
Median qSOFA (IQR) 1 (0–1) 1 (1–2) <0.001 2.419 (1.919–3.050)
Clinical variables
Body temperature
>38◦C 301 (44) 41 (28) <0.001
<36◦C 12 (2) 18 (12) <0.001 7.708 (3.636–16.386)
White blood cell count
>12,000/mm3 370 (54) 101 (68) 0.002 1.800 (1.234–2.626)
<4000/mm3 30 (4) 4 (3) 0.342
RR > 20/min or pCO2 < 32 mmHg 508 (75) 128 (86) 0.002 2.167 (1.312–3.580)
Heart rate > 90/min 509 (75) 122 (82) 0.05 1.576 (0.998–2.491)
Median BM (IQR)ˆ
C–reactive protein (mg/dL) 73 (20–160) 117 (52–205) <0.001 1.441 (1.231–1.687)
Lactate (mg/dL) 13 (9–19) 17 (12–26) <0.001 2.491 (1.788–3.471)
Procalcitonin (ng/mL) 0.33 (0.13–2.22) 0.9 (0.24–3.7) <0.001 1.178 (1.025–1.354)
sIL2Rα (pg/mL) 13234 (8026–22158) 20028 (12555–3269 <0.001 1.908 (1.508–2.414)
sTREM–1 (pg/mL) 375 (260–590) 633 (409–1001) <0.001 3.102 (2.332–4.126)
sPLA2GIIA (ng/mL) 31 (21–35) 31 (26–35) 0.041 1.638 (1.149–2.334)
Presepsin (pg/mL) 443 (280–908) 802(476–1450) <0.001 1.746 (1.446–2.107)
MR–proADM (nmol/L) 1.6 (1.1–2.5) 2.8 (1.9–4.7) <0.001 4.361 (3.033–6.269)
Etiology of SIRS
ni-SIRS 81(93) 6 (7) 0.05
Infections
Localized infections 95 (99) 1 (1) <0.001
Sepsis 400 (81) 96 (19) 0.096
Septic shock 23 (47) 26 (53) <0.001
d-SIRS 81 (81) 19 (19) 0.754
Abbreviations: OR = odds ratio, IQR = interquartile range, SOFA = sequential organ failure assessment, Qsofa =
quick sepsis-related organ failure assessment, RR = respiratory rate, ni-SIRS = non infective systemic inflammatory
response syndrome, d-SIRS = debatable systemic inflammatory response syndrome, sIL2Rα = soluble IL-2 receptor
α, sTREM-1 = soluble triggering receptor expressed on myeloid cell-1, sPLA2GIIA = soluble phospholipase A2
group IIA, and MR-proADM = mid-regional proadrenomedullin. ˆ Data are n◦ (%) unless otherwise specified.
The 30-day all-cause mortality rate was 18%. In Group 1, the qSOFA and SOFA score showed a
similar discriminatory power (AUROC for mortality 0.67; 95% CI 0.62–0.72 and 0.65; 95% CI 0.61–0.69,
respectively; p = 0.7565). Independent predictors of outcome, which were selected to build the three
predictive models, are shown in Table S1 (available in the Supplement). Model 1 represented an
“extended” qSOFA (eqSOFA1): it encompassed gender, age, Charlson Index score, qSOFA score,
body temperature <36 ◦C, heart rate >90/minute, and white blood cell count>12,000/mm3. Model 2 was
based on the combination of eqSOFA1, CRP, and lactate (eqSOFA1+CRP+lactate). Model 3 included
all of the latter and MR-proADM (eqSOFA1+CRP+lactate+MR-proADM). The receiver-operating
characteristic (ROC) curves are available in Figure 1.
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Figure 1. Group 1: Receiver operating characteristic curves of the sequential organ failure assessment
(SOFA), quick sepsis-related organ failure assessment (qSOFA), “extended” qSOFA derived in
Group 1 (eqSOFA1), eqSOFA1 integrated with serum concentrations of C-reactive protein and
lactate (eqSOFA1+CRP+lactate) and eqSOFA1 combined with serum concentrations of C-reactive
protein, lactate and mid–regional proadrenomedullin (eqSOFA1+CRP+lactate+MR-proADM) to predict
30-day mortality.
Prognostic performance of the three predictive models is reported in Table 2.
The AUROC of eqSOFA1 (0.79; 95% confidence interval [CI] 0.62–0.72), eqSOFA1+CRP+lactate
(0.81; 95% CI 0.75–0.83), and eqSOFA1+CRP+lactate+MR-proADM (0.83; 95% CI 0.80–0.87) significantly
exceeded that of qSOFA (all p<0.001). From the comparison of the three predictive models,
two conclusions could be drawn: first, the AUROC for mortality of eqSOFA1+CRP+lactate was
significantly better than that of eqSOFA1 (p = 0.01). Second, the addition of MR-proADM to
eqSOFA1+CRP+lactate resulted in a further improvement of its predictive ability of 30-day mortality
(p = 0.05).
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Table 2. Group 1: performance of the quick sepsis-related organ failure assessment (qSOFA), Model 1, Model 2, and Model 3.
AUROC Sensitivity Specificity NPV PPV LR- LR+
SOFA 0.65 0.70 0.53 0.83 0.25 0.51 1.57
(cut-off 3) (0.61–0.69) (0.61–0.78) (0.50–0.58) (0.81–0.91) (0.23–0.33) (0.39–0.67) (1.36–1.79)
qSOFA 0.67 0.46 0.82 0.84 0.36 0.66 2.58
(cut-off 2) (0.62–0.72) (0.38–0.54) (0.79–0.85) (0.82–0.90) (0.32–0.44) (0.56–0.77) (2.03–3.28)
eqSOFA1a 0.79 0.79 0.68 0.94 0.35 0.31 2.43
(cut-off* 0.16) (0.75–0.83) (0.72–0.86) (0.63–0.71) (0.91–0.97) (0.31–0.45) (0.23-0.43) (2.12–2.79)
eqSOFA1+CRP+lactateb 0.81 0.81 0.67 0.94 0.36 0.24 2.55
(cut-off* 0.15) (0.78–0.85) (0.77–0.89) (0.64–0.71) (0.90–0.96) (0.32–0.47) (0.17–0.35) (2.25–2.91)
eqSOFA1+CRP+lactate+MR-proADMc 0.83 0.82 0.75 0.94 0.40 0.30 3.09
(cut-off* 0.18) (0.80–0.87) (0.70–0.84) (0.71–0.78) (0.92–0.96) (0.36–0.51) (0.22–0.40) (2.64–3.61)
Abbreviations: SOFA= sequential organ failure assessment, eqSOFA1= “extended” quick sepsis-related organ failure assessment derived in Group 1, CRP= C-reactive protein, MR-proADM=
mid-regional proadrenomedullin, AUROC= area under the receiver operating characteristic curve, NPV=negative predictive value, PPV=positive predictive value, LR-=negative likelihood
ratio, and LR+=positive likelihood ratio. ()=95% Confidence Interval. aModel 1: gender, age, Charlson Index score, qSOFA score, body temperature <36◦C, heart rate >90/minute, and
white blood cell>12,000/mm3. bModel 2: gender, age, Charlson Index score, qSOFA score, body temperature <36◦C, heart rate >90/minute, white blood cell>12,000/mm3, Log C-reactive
protein, and Log lactate. cModel 3: gender, age, Charlson Index score, qSOFA score, body temperature <36◦C, heart rate >90/minute, white blood cell>12,000/mm3, Log C-reactive protein,
Log lactate, and Log mid-regional proadrenomedullin *Cut-off of the models were selected according to the Youden Index method.
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3.2. Group 2: Patients with Suspected Sepsis at ED Admission who Received a Definitive Diagnosis of Sepsis at
the end of Clinical Work-Up.
A total of 729 patients with suspected sepsis were definitively diagnosed with sepsis. There were
184 incomplete cases (Figure S1, available in the Supplement). Only the median concentration of
sTREM-1 was significantly higher in patients with complete data than in those with incomplete data
(p = 0.03). Table 3 summarizes the baseline characteristics of patients included in Group 2 (545),
their etiology, and source of infection.
Table 3. Group 2: baseline patient characteristics, etiology, and source of infection at the end of the
clinical work-up.
Survivor n = 423 (%) Non Survivor n = 122 (%) p OR
Male 242 (42) 56 (53) 0.027 0.635 (0.423–0.951)
Median age 80 (73–86) 85 (79–90) <0.001 1.043 (1.021–1.065)
Median Charlson index 3 (1–4) 3 (2–5) 0.142 1.072 (0.984–1.169)
Median SOFA (IQR) 3 (2–4) 4 (3–6) <0.001 1.27 (1.16–1.38)
Median qSOFA 1 (1–1) 2 (1–2) <0.001 2.776 (1.838–4.193)
Clinical variable
Body Temperature
>38◦C 204 (52) 39 (31) 0.001
<36◦C 9 (2) 16 (13) <0.001 6.943 (2.985–16.149)
White blood cell count
>12,000/mm3 241 (60) 82 (65) 0.043 1.800 (1234–2626)
<4000/mm3 18 (4) 4 (4) 0.629
Heart rate>90 bpm 311 (73) 109 (80) 0.095 2.167 (1.312–3.580)
RR>20/min or pCO2<32
mmHg 328 (x) 108 (x) 0.008 2.234 (1.224–4.078)
Median biomarker (IQR)
C-reactive protein (mg/dl) 129 (73-209) 130 (74-209) 0.039 1.369 (1.123–1.644)
Lactate (mg/dl) 14.4 (9.9-20) 18.3 (12.2-27.2) 0.007 1.863 (1.296–2.680)
Procalcitonin (ng/mL) 1.14 (0.36–5.09) 0.74 (0.26–5.47) 0.061 1.087 (0.934–1.266)
MR-proADM (nmol/L) 1.9 (1.3–3.2) 3.02 (1.96–5.04) <0.001 3.411 (2.275–5.113)
sIL2Rα (pg/ml) 15130 (9741–25220) 19446 (12596–31520) 0.014 1.630 (1.246–2.133)
Presepsin (pg/mL) 546 (341–1047) 781 (446–1423) 0.023 1.545 (1.239–1.926)
sTREM-1 (pg/mL) 418 (280–711) 619 (405–989) <0.001 2.359 (1.727–3.223)
sPLA2GIIA (ng/mL) 32.3 (27.4–36.3) 32.2 (28.8–36.5) 0.692 1.187 (0.768–1.834)
sTNFR-1 (pg/ml) 423.5 (320.4–634.0) 560.61 (388.2–712.6) <0.001 3.164 (1.946–5.143)
Source of infection
Single source 399 (94) 98 (80) 0.001
LRTI 240 (56) 71 (58) 0.024
Non LRTI 159 (38) 27 (22) 0.092
Multiple source 24 (6) 24 (20) <0.001
Etiology of infection
Clinically documented 261 (61) 80 (66) 0.345
Microbiologically
documented 174 (41) 51 (41) 0.932
Monomicrobial 144 (34) 39 (31) 0.669
Bacterial 133 (31) 41 (34) 0.814
Gram positive 44 (10) 19 (15) 0.002
Gram negative 77 (18) 11 (15) 0.037
Non bacterial 10 (2) 1 (0) 0.307
Polymicrobial 30 (7) 12 (1) 0.317
BSI 70 (16) 29 (24) 0.365
Non BSI 106 (25) 25 (20) 0.298
Abbreviations: OR= odds ratio, IQR= interquartile range, SOFA= sequential organ failure assessment,
qSOFA=quick sepsis-related organ failure assessment, RR=respiratory rate, LRTI=lower respiratory tract infections,
BSI=blood stream infections, MR-proADM=mid-regional proadrenomedullin, sIL2Rα=soluble IL-2 receptor α,
sTREM-1=soluble triggering receptor expressed on myeloid cell-1, sPLA2GIIA= soluble phospholipase A2 group
IIA, and sTNFR-1-= soluble tumor necrosis factor receptor-1 (sTNFR-1). Data are n◦ (%) unless otherwise specified.
A total of 122 patients died within 30 days from ED admission (23%). In Group 2, we did not find
a statistically significant difference between the AUROC of the qSOFA and SOFA score in predicting
sepsis outcome (0.66; 95% CI 0.61-0.71 and 0.65; 95% CI 0.59-0.69, respectively; p = 0.5639).
The same method of analysis was applied in Group 2 as in Group 1. The only difference was that,
in Group 2, sTNFR-1 was added to the panel of biomarkers already tested in Group 1. This choice
was elicited by the recent findings obtained in favor of using sTNFR-1 for sepsis prognostication in
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the intensive care unit (ICU) [17]. In accord with the final list of the independent predictors of 30-day
mortality (Table S2, available in the Supplement), the three predictive models were built as follows:
Model 4 included gender, age, Charlson Index, qSOFA, body temperature < 36◦C, and heart rate
>90/min (eqSOFA2); Model 5 added CRP to eqSOFA2 (eqSOFA2+CPR); and Model 6 enclosed eqSOFA2,
CRP, and MR-proADM (eqSOFA2+CRP+MR-proADM). Sensitivity, specificity, NPV, PPV, LR-, and LR+
of the three models are reported in Table 4.
Their ROC curves are shown in Figure 2.
Figure 2. Group 2: Receiver operating characteristic curves of the sequential organ failure
assessment (SOFA), quick sepsis-related organ failure assessment (qSOFA), “extended” qSOFA2
derived in Group 2 (eqSOFA2), eqSOFA2 integrated with serum concentrations of C-reactive protein
(eqSOFA2+CRP) and eqSOFA2 combined with serum concentrations of C-reactive protein and
mid–regional proadrenomedullin (eqSOFA2+CRP+MR-proADM) to predict 30-day mortality.
eqSOFA2 (AUROC 0.73; 95% CI 0.68–0.78), eqSOFA2+CRP (AUROC 0.75; 95% CI 0.70–0.79),
and eqSOFA2+CRP+MR-proADM (AUROC 0.80; 95% CI 0.76–0.84) proved to be significantly better
than qSOFA (AUROC 0.66; 95% CI 0.61–0.71; all p < 0.001) in predicting outcome. We did not observe
a significant difference between the AUROC for mortality of eqSOFA2 and eqSOFA2+CRP (p = 0.068).
On the contrary, the prognostic performance of eqSOFA2+CRP was significantly improved by its
integration with MR-proADM (p = 0.002).
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Table 4. Group 2: performance of the quick sepsis-related organ failure assessment (qSOFA), Model 4, Model 5, and Model 6.
AUROC Sensitivity Specificity NPV PPV LR- LR+
SOFA 0.65 0.75 0.45 0.83 0.28 0.52 1.39
(cut-off 3) (0.59–0.69) (0.67–0.80) (0.40–0.50) (0.81–0.88) (0.24–0.38) (0.37–0.70) (1.21–1.59)
qSOFA 0.66 0.49 0.78 0.80 0.40 0.65 2.29
(cut-off 2) (0.61–0.71) (0.40–0.58) (0.74–0.82) (0.79–0.87) (0.34–0.49) (0.54–0.77) (1.77–2.95)
eqSOFA2a 0.73 0.52 0.84 0.85 0.48 0.58 3.21
(cut-off* 0.30) (0.68–0.78) (0.42–0.61) (0.80–0.87) (0.81–0.89) (0.42–0.57) (0.48–0.70) (2.43–4.24)
eqSOFA2+CRPb 0.75 0.71 0.67 0.88 0.38 0.43 2.14
(cut-off* 0.22) (0.70–0.79) (0.62–0.79) (0.62–0.71) (0.84–0.91) (0.33–0.48) (0.32–0.57) (1.79–2.55)
eqSOFA2+CRP+MR-proADMc 0.80 0.83 0.67 0.93 0.42 0.26 2.50
(cut-off* 0.18) (0.76–0.84) (0.75–0.89 (0.62–0.71) (0.89–0.94) (0.37–0.55) (0.17–0.38) (2.14–2.93)
Abbreviations: SOFA= sequential organ failure assessment, qSOFA= quick sepsis-related organ failure assessment, eqSOFA2= “extended” quick sepsis-related organ failure assessment
derived in Group 2, CRP= C reactive protein, MR-proADM= mid-regional proadrenomedullin, AUROC= area under the receiver operating characteristic curve, NPV=negative predictive
value, PPV=positive predictive value, LR-=negative likelihood ratio, LR+=positive likelihood ratio. ()=95% Confidence Interval. aModel 4: gender, age, Charlson Index score, qSOFA score,
body temperature < 36◦C, and heart rate >90/min. bModel 5: gender, age, Charlson Index score, qSOFA score, body temperature < 36◦C, heart rate >90/min, and Log C-reactive protein.
cModel 6: gender, age, Charlson Index score, qSOFA score, body temperature < 36◦C, heart rate >90/min, Log C-reactive protein, and Log MR-proADM. * Cut-off of the models were
selected according to the Youden Index method.
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4. Discussion
Patients initially suspected to have an infection, but who were deemed ni-SIRS on expert review,
were excluded from the first prospective study, which was conducted to validate the prognostic
accuracy of qSOFA in patients with suspected sepsis at ED admission [25]. In our study, 10% of these
patients had an ni-SIRS result at the end of clinical work-up. These epidemiological findings resembled
that of previous works performed in the same setting [26,27], and reinforced the need to evaluate the
prognostic performance of qSOFA in a population that mirrors “real life” patients with suspected sepsis
at ED admission. Therefore, we assessed the predictivity of qSOFA not only in patients definitively
diagnosed with sepsis (Group 2), but also in undifferentiated patients with suspected sepsis (Group 1).
Interestingly, the prognostic accuracy shown by qSOFA in Group 1 and in Group 2 was similarly far
from perfection (AUROC 0.67 and 0.66, respectively). To corroborate this finding, we have to highlight
that an AUROC for mortality under 0.7 was also reached by qSOFA in the largest prospective study
ever performed to assess its prognostic accuracy in patients with suspected sepsis at ED admission3.
As stated in the method section, the first step to enhance the predictivity of qSOFA entailed its
combination with the clinical variables independently associated with the outcome in each cohort.
In Group 1, this meant building a predictive model (eqSOFA1) based on gender, age, Charlson Index
score, qSOFA score, and three of the SIRS criteria (body temperature <36◦C, heart rate >90/minute,
and white blood cell count>12,000/mm3). The same clinical variables, except for white blood cell count
>12,000/mm3, composed the eqSOFA2 in Group 2. It follows that, eqSOFA is not a new warning score,
but rather the synthesis, adjusted for age, gender, and comorbidities, of two existing ones. For the
first time in the literature, the SIRS criteria and qSOFA were proven to act synergistically to predict
outcome in patients with suspected sepsis at ED admission; furthermore, studies do not exist that
have derived a biomarker-enriched model predictive of prognosis specifically for undifferentiated
patients with suspected sepsis (eqSOFA1) and for those, among them, definitively diagnosed with
sepsis (eqSOFA2). Notably, the prognostic performance of both eqSOFA1 and eqSOFA2 exceeded that of
qSOFA (AUROC 0.79 and 0.73, respectively; all p < 0.001). When eqSOFA1 and eqSOFA2 were enriched
with the biomarkers that were proved to be independently associated with the outcome in each group,
their predictive ability of 30-day mortality was further enhanced. Of the six prognostic models derived
in this study, eqSOFA1+CRP+lactate+MR-proADM in Group 1, and eqSOFA2+CRP+MR-proADM in
Group 2 exhibited the highest AUROC for mortality with the maximum expenditure of biomarkers
(0.83 and 0.80, respectively). A similar performance was reached by Mikacenic et al in the largest
study ever conducted to derive and validate a biomarker-enriched model to predict sepsis outcome
in the ICU (AUROC 0.79) [16]. Among all of the putative biomarkers, only IL-8 and sTNFR-1
were included in that “robust” model. We may speculate that if the prognostic performance of
eqSOFA1+CRP+lactate+MR-proADM and eqSOFA2+CRP+MR-proADM was to be confirmed in the
ICU setting, the key issue in favor of using our models would be that both of these model could
be promptly implemented in clinical practice with CRP, lactate, and MR-proADM, unless IL-8 and
sTNFR-1, are already available for prime time.
Seeing as the introduction of qSOFA, as compared with SIRS-based prognostication, has enhanced
the specificity of the prediction of mortality associated with sepsis, but at the expense of sensitivity2,
our analysis focused on predictive models that exhibited the highest NPV, possibly, with the minimum
expenditure of biomarkers. The main goal of such an approach was to identify the models with the
best ability to rule out the outcome, while easing the financial burden of the use of biomarkers in the
health care system. The proper identification of subjects at low risk of death is particularly pressing
in Europe, where, as in other countries with poor availability of ICU beds, most of the patients with
suspected sepsis are initially managed in the ED and then transferred to general wards [28]. It would
be desirable to identify a screening tool that could support ED physicians in the safe admission of
patients with suspected sepsis outside the ICU, to avoid the risk of a less than optimum resuscitation.
Unfortunately, qSOFA did not meet this need in either Group 1 (NPV = 0.84; 95% CI 0.82-0.90) or
Group 2 (NPV = 0.80; 95% CI 0.79-0.87). Both eqSOFA1 and eqSOFA2 outperformed qSOFA in ruling
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out poor prognosis (all p < 0.001). However, depending on the etiology of SIRS, eqSOFA could
be employed as a “stand alone” model for the safe identification of subjects at low risk of death
among patients with suspected sepsis at ED admission. In fact, while the NPV of eqSOFA1 was
sufficiently high to support its use for a safe ruling out of patients at high risk of mortality (0.94; 95%
CI 0.91-0.97), the NPV eqSOFA2 was too low for this purpose (0.85; 95% CI 0.81-0.89). The contribution
of biomarkers to further improve the NPV of eqSOFA was not straightforward in either group. In
fact, the ability of eqSOFA1 to rule out poor prognosis was not ameliorated by its enrichment with
CRP, lactate, and MR-proADM (0.94), whereas CRP, and MR-proADM significantly increased the
NPV of eqSOFA2 to 0.93 (p < 0.001). Outstandingly, eqSOFA1 and eqSOFA2+CRP+MR-proADM
obtained the highest NPV to identify the patients at low risk of death, using as few biomarkers as
possible, and without the need to maximize their threshold score [17]. We want to emphasize that
eqSOFA1 in Group 1 and eqSOFA2+CRP+MR-prodADM in Group 2 reached such a performance
without worsening the corresponding PPV of qSOFA (Group 1 = 0.36 and 0.40, respectively; Group 2
= 0.40 and 0.42, respectively).
These findings can be translated to clinical practice as follows: eqSOFA1 could be particularly
helpful for recognizing subjects at low risk of death among patients with suspected sepsis at ED
admission, for whom it is often challenging to pose a definitive diagnosis of sepsis, because the
early presentation of many acute pathologies closely mimics that of sepsis, and the results of the
microbiological work-up are usually not available. When the diagnosis of sepsis is already established
(which occurs mainly in general wards), eqSOFA2+CRP+MR-proADM should be used in place of
eqSOFA1, to rule out patients at high risk of mortality with the same high predictivity exhibited by
eqSOFA1 in undifferentiated patients.
This is the largest sample to date of patients with suspected sepsis at ED admission, who had all
eight biomarkers measured. It is worth nothing that, for the first time in the literature, this panel of
conventional and experimental biomarkers (including two of the most promising, MR-proADM and
sTNFR-1) was compared side by side with qSOFA in the same study for sepsis prognostication. In the
light of these premises, some interesting conclusions can be drawn. First, MR-proADM, as standalone
biomarker to predict outcome, exhibited an AUROC higher than that of both qSOFA and all the other
biomarkers independently from etiology of SIRS (Table S3 and Table S4). Second, among all the
biomarkers assayed in our study, only CRP and MR-proADM were independently associated with
30-day mortality in either Group 1 or Group 2. Third, CRP and MR-prodADM proved to be addictive
to eqSOFA in predicting prognosis in both cohorts. Fourth, lactate resulted an independent biomarker
of prognosis only in Group 1: it contributed with eqSOFA1, CRP and MR-proADM to build the model
with the highest AUROC to predict mortality (qSOFA1+CRP+lactate+MR-proADM). Fifth, biomarkers
were useless in improving the NPV of eqSOFA1; however, in Group 2, CRP and MR-proADM were
necessary to significantly increase the ability of eqSOFA2 in ruling out adverse outcome.
The study does have limitations. A total of 304 undifferentiated patients with suspected sepsis
did not enter the final analysis. To mitigate the concerns related to the generalizability of eqSOFA1 and
eqSOFA+CRP+MR-proADM2, we validated our models in two cohorts of patients initially held out
due to missing data. The details are discussed in the Supplement. In summary, in terms of AUROC,
the prognostic performance of eqSOFA1 and eqSOFA2+CRP+MR-proADM in the inception (0.79 and
0.80 [Figure S2], respectively) and validation cohorts (0.80 and 0.82 [Figure S3], respectively) was
similar (p = 0.82, p = 0.81, respectively). Moreover, we did not assess the correlation of eqSOFA1 and
eqSOFA2+CRP+MR-proADM with the length of hospital stay, disease progression, or requirement for
ICU care after ED admission.
In conclusion, we have derived and validated two prognostic models that were proven to
be more robust than qSOFA and SOFA in predicting mortality and in ruling out the high risk of
death among patients with suspected sepsis at ED admission, either undifferentiated (eqSOFA1)
or definitively diagnosed with sepsis (eqSOFA2+CRP+MR-proADM). The two predictive models,
which were composed of clinical variables routinely measured at ED admission, and encompassed
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biomarkers that are already available for prime time, need to be externally validated prior to any
clinical application.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/4/1205/s1,
Figure S1. Flow chart describing the design of the inception (Group 1 and Group 2) and validation cohorts. Figure S2.
Receiver operating characteristic curve of “extended” quick sepsis-related organ failure assessment derived in
Group 1 (eqSOFA1) to predict 30-day mortality in the validation cohort. Figure S3. Receiver operating characteristic
curve of the “extended” quick sepsis-related organ failure assessment derived in Group 2 integrated with serum
concentrations of C-reactive protein and mid –regional proadrenomedullin (eqSOFA2+CRP+MR-proADM) to
predict 30-day mortality in the validation cohort. Table S1. Independent predictors of 30-day mortality in Group 1:
multivariable analysis. Table S2. Independent predictors of 30-day mortality in Group 2: multivariable analysis.
Table S3. Prognostic performance of the biomarkers assayed in Group 1. Table S4. Prognostic performance of the
biomarkers assayed in Group 2.
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